EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Boosting maternal and neonatal anti–SARS-CoV-2 humoral immunity using a third mRNA vaccine dose

Adva Cahen-Peretz, Lilah Tsaitlin-Mor, Hadas Allouche Kam, Racheli Frenkel, Maor Kabessa, Sarah M Cohen, Michal Lipschuetz, Esther Oiknine-Djian, Sapir Lianski, Debra Goldman-Wohl, Asnat Walfisch, Michal Kovo und 4 weitere

JCI Insight · 10.01.2023 · 8 (1)

DOI: 10.1172/jci.insight.158646 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCI Insight, online erschienen am 10.01.2023. Verfasst von Adva Cahen-Peretz und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Hadassah Hebrew University Medical Center, Jerusalem, Israel. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Science Foundation, Hadassah Medical Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND. To minimize COVID-19 pandemic burden and spread, 3-dose vaccination campaigns commenced worldwide. Since patients who are pregnant are at increased risk for severe disease, they were recently included in that policy, despite the lack of available evidence regarding the impact of a third boosting dose during pregnancy, underscoring the urgent need for relevant data. We aimed to characterize the effect of the third boosting dose of mRNA Pfizer BNT162b2 vaccine in pregnancy. METHODS. We performed a prospective cohort study of anti–SARS-CoV-2 antibody titers ( n = 213) upon delivery in maternal and cord blood of naive fully vaccinated parturients who received a third dose ( n = 86) as compared with 2-dose recipients ( n = 127). RESULTS. We found a robust surge in maternal and cord blood levels of anti–SARS-CoV-2 titers at the time of delivery, when comparing pregnancies in which the mother received a third boosting dose with 2-dose recipients. The effect of the third boosting dose remained significant when controlling for the trimester of last exposure, suggesting additive immunity extends beyond that obtained after the second dose. Milder side effects were reported following the third dose, as compared with the second vaccine dose, among the fully vaccinated group. CONCLUSION. The third boosting dose of mRNA Pfizer BNT162b2 vaccine augmented maternal and neonatal immunity with mild side effects. These data provide evidence to bolster clinical and public health guidance, reassure patients, and increase vaccine uptake among patients who are pregnant. FUNDING. Israel Science Foundation KillCorona grant 3777/19; Research grant from the “Ofek” Program of the Hadassah Medical Center.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19Infant, NewbornFemalePregnancyHumansBNT162 VaccineImmunity, HumoralPandemicsProspective StudiesMothersRNA, MessengermRNA Vaccines

Stichwörter der Autor:innen

Adaptive immunityCOVID-19EpidemiologyObstetrics/gynecologyVaccines

Substanzen

BNT162 VaccineRNA, MessengermRNA Vaccines

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
  • Clinical Virology Unit, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Department of Obstetrics and Gynecology, Meir Medical Center, Kfar Saba, Israel.
  • Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Lautenberg Center for General and Tumor Immunology, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Förderung

  • Israel Science Foundation
  • Hadassah Medical Organization

Zitieren

APA

Cahen-Peretz, A., Tsaitlin-Mor, L., Allouche Kam, H., Frenkel, R., Kabessa, M., Cohen, S. M., Lipschuetz, M., Oiknine-Djian, E., Lianski, S., Goldman-Wohl, D., Walfisch, A., Kovo, M., Neeman, M., Wolf, D. G., Yagel, S., & Beharier, O. (2023). Boosting maternal and neonatal anti–SARS-CoV-2 humoral immunity using a third mRNA vaccine dose. JCI Insight, 8(1). https://doi.org/10.1172/jci.insight.158646

Vancouver

Cahen-Peretz A, Tsaitlin-Mor L, Allouche Kam H, Frenkel R, Kabessa M, Cohen SM, et al. Boosting maternal and neonatal anti–SARS-CoV-2 humoral immunity using a third mRNA vaccine dose. JCI Insight. 2023;8(1). doi:10.1172/jci.insight.158646

BibTeX
@article{CahenPeretz2023,
  author = {Cahen-Peretz, Adva and Tsaitlin-Mor, Lilah and Allouche Kam, Hadas and Frenkel, Racheli and Kabessa, Maor and Cohen, Sarah M and Lipschuetz, Michal and Oiknine-Djian, Esther and Lianski, Sapir and Goldman-Wohl, Debra and Walfisch, Asnat and Kovo, Michal and Neeman, Michal and Wolf, Dana G and Yagel, Simcha and Beharier, Ofer},
  title = {Boosting maternal and neonatal anti–SARS-CoV-2 humoral immunity using a third mRNA vaccine dose},
  journal = {JCI Insight},
  year = {2023},
  volume = {8},
  number = {1},
  doi = {10.1172/jci.insight.158646}
}
Kostenlos starten →